Mounjaro Injectable Pen 2.5 mg: What the Starting Dose Is For

Step 1 (Taking the 2.5 mg injection correctly from week one

The KwikPen is injected once a week into the abdomen, thigh, or upper arm) pick a spot and rotate the site each time to avoid skin reactions building up. The day of the week you choose in week one becomes your injection day going forward; consistency matters, though the patient information leaflet gives detail on what to do if you need to shift the day slightly. Mounjaro KwikPens are refrigerated at 2–8°C; if you are travelling or the pen has been out of the fridge, refer to the SmPC on the electronic Medicines Compendium for the exact room-temperature window, it is specific and matters for the medicine's stability.

A question our prescribers hear regularly is whether injecting from the 5 mg pen at a lower setting is possible instead of using the 2.5 mg pen. It is not, the process for injecting 2.5 mg from a 5 mg pen is sometimes confused with standard practice, but the pens are distinct devices calibrated to their labelled dose. Your 2.5 mg pen delivers 2.5 mg per click; that is the dose you receive, no adjustment required.

The Mounjaro 2.5 mg pen looks and works identically to the higher-strength versions, same mechanism, same injection technique. If you are unsure about the physical steps involved, the separate injection technique guide covers the process in detail, and the same steps apply at 2.5 mg.

Step 2, Understanding what the 2.5 mg dose is and is not doing

There is a widespread assumption that if 2.5 mg is not producing quick weight loss, the treatment is not working. That misreads what this dose is designed to do. The licensed schedule starts at 2.5 mg precisely because tirzepatide slows gastric emptying and acts on appetite-regulating pathways simultaneously; introducing both effects at full therapeutic strength from week one produces significant nausea in many people. The starter dose gives your gut time to adapt.

The NHS tirzepatide medicines page confirms this titration approach and notes that the dose is usually increased every four weeks until the maintenance dose is reached. In the SURMOUNT-1 trial (which enrolled 2,539 adults with obesity) the weight reductions of around 20–21% at the 15 mg maintenance dose were achieved over 72 weeks, not four. That context matters when judging progress early in treatment.

If side effects at 2.5 mg are still uncomfortable after the first few weeks, speak to your prescriber before making any changes. Reducing, pausing, or extending time at this dose is a clinical decision, not one to make unilaterally. The Mounjaro overview page covers the full picture of how the medicine works in the body.

Step 3, Moving from 2.5 mg to the next dose, and what to expect

After four weeks at 2.5 mg, most patients move to the 5 mg pen under their prescriber's plan. The 5 mg pen is the next step in the same titration ladder, and the jump is modest by design. Your prescriber will want to know how the starter dose went (any side effects, how appetite changed, how you are sleeping and feeling) before confirming the increase.

For patients who are finding 2.5 mg well tolerated and are keen to understand the longer journey ahead, the 7.5 mg step is typically where prescribers start to see meaningful clinical effect for many people, though the right maintenance dose is individual. NICE's appraisal of tirzepatide, TA1026, notes that continuing treatment is reviewed if less than 5% weight loss is achieved after six months at the highest tolerated dose, so the full picture only emerges over months, not weeks.

One practical note: if you ever want to check whether a pharmacy offering Mounjaro is legitimate, the GPhC pharmacy register is the right place to look. A registered dispensing pharmacy carries a verifiable premises number, ours is 9012878. For context on what private treatment typically costs once you're established on treatment, the Mounjaro cost and access page sets out the landscape without surprises.